MeSH tree: D03.383.742.680
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form ...
Jun 4, 2026
0
3
A national team of cancer researchers led by Drs. Kenneth Shroyer and Natalia Marchenko at Stony Brook Medicine, and Dr. Luisa Escobar-Hoyos of Yale School of Medicine, investigated the role of Keratin 17 (K17) in the most ...
May 20, 2026
0
7
Chemotherapy can be life-saving for many patients, but not all tumors respond—and some that do, may eventually become resistant. Investigators at Houston Methodist have identified a possible explanation for this resistance, ...
May 18, 2026
0
7
Three clinically available drugs could pave the way for safer and more effective treatments for one of the most aggressive forms of childhood leukemia, a new study published in the journal HemaSphere suggests.
Apr 27, 2026
0
4
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows. The findings apply to serious cases after tumors have already spread ...
Apr 22, 2026
0
10
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and ...
Mar 18, 2026
0
10
A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and other therapies directly to tumors, killing cancer cells without generating an immune response or ...
Feb 6, 2026
0
117
A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel DNA-based therapy, Elenagen, ...
Jan 12, 2026
0
14
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.
Dec 29, 2025
0
97
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.
Aug 13, 2025
0
52
